Innovative Therapeutics Focus Keros Therapeutics is heavily invested in developing therapies targeting disorders related to transforming growth factor-beta signaling, which presents opportunities to collaborate with biotech and pharma companies focusing on signal modulation and neurological or muscular diseases.
Pipeline Expansion The company is actively progressing multiple candidate drugs such as KER-050, KER-012, and KER-065, particularly for muscular dystrophy and obesity, signaling readiness for clinical partnerships or licensing deals to accelerate market entry.
$25M$50M
$10M$25M
$50M$100M
$25M$50M
$1M$10M
$100M$250M
$10M$25M
$1M$10M
$10M$25M
$1MKeros Therapeutics uses 8 technology products and services including Google Hosted Libraries, Medidata, Microsoft Entra ID, and more. Explore Keros Therapeutics's tech stack below.
| Keros Therapeutics Email Formats | Percentage |
| FLast@kerostx.com | 82% |
| First@kerostx.com | 9% |
| First.Last@kerostx.com | 6% |
| Last.First@kerostx.com | 3% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
At Keros, our mission is to innovate therapies that have the potential to shift the treatment paradigm for a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins.
Company Overview
Media & News
Funding & FinancialsKeros Therapeutics has raised a total of $140M of funding over 5 rounds. Their latest funding round was raised on Jan 03, 2024 in the amount of $140M.
Keros Therapeutics's revenue is estimated to be in the range of $1M
Funding & FinancialsKeros Therapeutics has raised a total of $140M of funding over 5 rounds. Their latest funding round was raised on Jan 03, 2024 in the amount of $140M.
Keros Therapeutics's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com